Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Spyropoulos AC, et al. Among authors: hiatt wr. N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26. N Engl J Med. 2018. PMID: 30145946 Free article. Clinical Trial.
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob GE. Spyropoulos AC, et al. Among authors: hiatt wr. J Am Coll Cardiol. 2020 Jun 30;75(25):3140-3147. doi: 10.1016/j.jacc.2020.04.071. J Am Coll Cardiol. 2020. PMID: 32586587 Free PMC article. Clinical Trial.
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Capell WH, et al. Among authors: hiatt wr. Am Heart J. 2021 May;235:12-23. doi: 10.1016/j.ahj.2021.02.001. Epub 2021 Feb 9. Am Heart J. 2021. PMID: 33577800 Free PMC article.
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.
Ageno W, Lopes RD, Goldin M, Yusen RD, Albers GW, Elliott GC, Halperin JL, Hiatt WR, Maynard G, Steg PG, Weitz JI, Suh E, Lu W, Barnathan ES, Raskob GE, Spyropoulos AC. Ageno W, et al. Among authors: hiatt wr. J Thromb Haemost. 2021 Nov;19(11):2772-2780. doi: 10.1111/jth.15477. Epub 2021 Aug 17. J Thromb Haemost. 2021. PMID: 34314574 Free PMC article. Clinical Trial.
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Spyropoulos AC, Raskob GE, Cohen AT, Ageno W, Weitz JI, Spiro TE, Lu W, Lipardi C, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Sugarmann C, Barnathan ES. Spyropoulos AC, et al. Among authors: hiatt wr. Circulation. 2022 May 10;145(19):1471-1479. doi: 10.1161/CIRCULATIONAHA.121.057847. Epub 2022 Apr 7. Circulation. 2022. PMID: 35389229 Free article.
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.
Spyropoulos AC, Goldin M, Ageno W, Albers GW, Elliott CG, Hiatt WR, Halperin JL, Maynard G, Steg PG, Weitz JI, Spiro TE, Lu W, Marsigliano J, Raskob GE, Barnathan ES. Spyropoulos AC, et al. Among authors: hiatt wr. TH Open. 2022 Jul 11;6(3):e177-e183. doi: 10.1055/s-0042-1750379. eCollection 2022 Jul. TH Open. 2022. PMID: 36046208 Free PMC article.
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. Raskob GE, et al. Among authors: hiatt wr. Thromb Haemost. 2016 Jun 2;115(6):1240-8. doi: 10.1160/TH15-09-0756. Epub 2016 Feb 4. Thromb Haemost. 2016. PMID: 26842902 Free article. Clinical Trial.
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.
Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators. Goldenberg NA, et al. Among authors: hiatt wr. J Thromb Haemost. 2015 Sep;13(9):1597-605. doi: 10.1111/jth.13038. Epub 2015 Aug 11. J Thromb Haemost. 2015. PMID: 26118944 Free PMC article. Clinical Trial.
Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátyás L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Bonaca MP, et al. Among authors: hiatt wr. N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28. N Engl J Med. 2020. PMID: 32222135 Clinical Trial.
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC. Goldin M, et al. Among authors: hiatt wr. Thromb Haemost. 2021 Dec;121(12):1684-1695. doi: 10.1055/a-1475-2351. Epub 2021 May 28. Thromb Haemost. 2021. PMID: 33823560
393 results